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Background: Extracellular vesicles (EVs) (isolated from blood plasma) are currently
being extensively researched, both as biomarkers and for their therapeutic possibilities.
One challenging aspect to this research is the efficient isolation of high-purity EVs from
blood plasma in quantities sufficient for in vivo experiments. In accordance with this
challenge, the aim of this study was to develop an isolation method in which to separate
the majority of EVs from major impurities such as lipoprotein particles and the abundant
plasma proteins albumin and fibrinogen.
Methods: Samples of rat blood were centrifuged to remove cells, platelets, large
EVs and protein aggregates without prior filtration. Density gradient ultracentrifugation
was performed by loading plasma sample onto 50, 30, and 10% iodixanol layers
and then centrifuged at 120,000 × g for 24 h. Ten fractions (F1-10) were collected
from top to bottom. Fractions with the highest EV content were further purified by
ultracentrifugation, size exclusion, or bind-elute chromatography. Efficiency and purity
were assessed by Western blots. Morphology and size distribution of particles were
examined by dynamic light scattering and electron microscopy (EM).
Results: The highest band intensities of EV markers Alix, Tsg101 and CD81 were
detected by Western blot in F6 of small-scale DGUC (61.5 ± 10.4%; 48.1 ± 5.8%;
41.9 ± 3.8%, respectively) at a density of 1.128–1.174 g/mL, where the presence of
vesicles with a mean diameter of 38 ± 2 nm was confirmed by EM and DLS. Only
1.4± 0.5% of LDL and chylomicron marker, 3.0± 1.3% of HDL marker, and 9.9± 0.4%
of albumin remained in the EV-rich F6. However, 32.8 ± 1.5% of the total fibrinogen
beta was found in this fraction. Second-step purification by UC or SEC did not improve
EV separation, while after BEC on HiScreen Capto Core 700 albumin and lipoprotein
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contamination were below detection limit in EV-rich fractions. However, BEC decreased
efficiency of EV isolation, and fibrinogen was still present in EV-rich fractions.
Conclusion: This is the first demonstration that DGUC is able to markedly reduce the
lipoprotein content of EV isolates while it separates EVs with high efficiency. Moreover,
isolation of lipoprotein- and albumin-free EVs from blood plasma can be achieved by
DGUC followed by BEC, however, on the expense of reduced EV yield.
Keywords: extracellular vesicles, isolation, exosomes, plasma, iodixanol, density gradient ultracentrifugation,
bind-elute chromatography
INTRODUCTION
Extracellular vesicles (EVs) are released by various cell types and
transport different proteins, nucleic acids and lipids generally
representing the parental cell (Raposo and Stoorvogel, 2013).
EVs have been linked to several physiological or pathological
processes as mediators (e.g., immune response, tumorigenesis
or cardioprotection; (Giricz et al., 2014; Barile et al., 2017;
Sluijter et al., 2018) and they have been shown to have
the potential for clinical applications, both as biomarkers or
drug delivery systems (D’Souza-Schorey and Clancy, 2012). For
example, the role of EVs in the immune system highlights
their potential in immunomodulatory therapies, as EVs could
be applied in antigen presentation or even as vaccines (Wang
et al., 2018). While miRNA and mRNA cargo of EVs allow
the use of EVs isolated from blood in cancer diagnostics
(Rolfo et al., 2014; Krug et al., 2018). Further research on
the composition, in vivo functionality, and pharmacological
applicability of EVs isolated from blood plasma requires large
amounts of intact vesicles purified from other, non-vesicular
plasma components, for which suitable isolation methods have
not yet been demonstrated.
Currently, the most commonly applied methods for EV
isolation from blood plasma are based on differential UC, SEC,
filtration, or the combination thereof (Kalra et al., 2013; Boing
et al., 2014; Baranyai et al., 2015; Welton et al., 2015; Mol
et al., 2017; Sluijter et al., 2018). Isolation of pure EVs from
plasma samples faces numerous challenges including aggregation
of vesicles (Linares et al., 2015), significant contamination with
soluble plasma proteins (Kalra et al., 2013; Welton et al.,
2015), and co-isolation with EV-sized lipoproteins (Yuana et al.,
2014; Sodar et al., 2016), which could hinder functional and
analytical studies on EVs since certain proteins and, particularly
lipoproteins, may carry microRNA (Yuana et al., 2014). It
was also reported that UC- or SEC-based isolation achieve
low recovery of EVs, which may limit their applicability for
most analytical and in vivo therapeutical goals (Baranyai et al.,
2015). Thus, there is a need for more efficient isolation
protocols.
Abbreviations: Apo B100/48, apolipoprotein B100/48; ApoA1, apolipoprotein
A1; BEC: bind-elute chromatography; CIP, clean-in-place fraction; DGUC, density
gradient ultracentrifugation; DLS, dynamic light scattering; EF, eluted fraction;
EM, electron microscopy; ES, Exo-Spin fraction; EV, extracellular vesicle; F,
fraction; FGB, fibrinogen beta chain; P6, pellet; PFP, platelet-free plasma; RIPA,
radio immunoprecipitation assay buffer; S6, supernatant; SEC, size-exclusion
chromatography; UC, ultracentrifugation.
Separating particles on the basis of their buoyant densities
by DGUC using sucrose or iodixanol has been used for EV
isolation from cell culture supernatant and body fluids, most
often coupled with other methods such as UC or SEC (Tauro
et al., 2012; Iwai et al., 2016). Although, DGUC may result
in EVs with less contaminant than that which is obtained by
other methods (Tauro et al., 2012; Kalra et al., 2013; Iwai
et al., 2016; Konadu et al., 2016; Kowal et al., 2016; Karimi
et al., 2018), available isolation strategies involving DGUC have
low yield due to the multiple-step protocols (Kalra et al.,
2013; Momen-Heravi et al., 2013; Baranyai et al., 2015). In
2018, it was demonstrated that DGUC with iodixanol might
successfully separate EVs isolated from blood plasma from
similar sized lipoproteins without prior UC; however, low yield
and contamination of soluble protein remained significant issues
(Karimi et al., 2018). Therefore, further optimization of EV
isolation is required.
Recently innovative technologies have emerged for EV
isolation. For instance, Corso et al. (2017) reported that by using
BEC on Capto Core 700 column cell culture EVs isolated could
be separated with high efficiency from protein contaminants.
This column does not only exclude EV-sized particles, but
also captures negatively charged or hydrophobic proteins and
other molecules. Nevertheless, no data has been reported on
the applicability of BEC for the isolation of EVs from complex
biological fluids such as blood plasma.
Thus, the main objectives of our study were (1) to establish
a iodixanol-DGUC protocol for efficient isolation of EVs from
blood plasma, (2) to test if BEC could be applied for the efficient
isolation of EVs isolated from blood plasma in combination with
DGUC, and (3) to assess the yield and separation efficiency of the
applied protocols, and (4) to monitor the presence of some of the
most abundant soluble protein and lipoprotein contaminations
of EV isolates.
MATERIALS AND METHODS
For a detailed description of the methods used, please check
‘Supplementary Methods,’ in this paper. Since we did not apply
filtering during separation and since the size ranges of exosomes
and MVs may overlap, we use the generic term “extracellular
vesicles” to refer to the vesicles isolated here, which is in
accordance with previous recommendations (Gould and Raposo,
2013).
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Animal Welfare
The investigation conforms to the Guide for the Care and Use
of Laboratory Animals published by the US National Institutes
of Health (NIH publication No. 85–23, revised 1996), to the EU
Directive (2010/63/EU) and was approved by the animal ethics
committee of the Semmelweis University, Budapest, Hungary
(PE/EA/1784-7/2017).
Blood Collection and Sample
Preparation
Whole blood was collected from the caudal vena cava of male
Wistar rats weighing 200–300 g into Anticoagulant Citrate
Dextrose-A vacuum tubes. PFP was obtained by centrifuging
samples two times at 2,500 × g at 4◦C, for 15 min as previously
described (Baranyai et al., 2015). PFP was then centrifuged at
18,000 × g at 4◦C, for 90 min, (cleared PFP), then stored at
−80◦C until isolation procedure (Figure 1). To compare the
results of EV isolated from frozen cleared PFP, a parallel study
was also carried out on EVs isolated from fresh samples without
prior freezing.
Iodixanol Density Gradient
Ultracentrifugation
DGUC was performed as previously described by Karimi et al.
(2018) with modifications. OptiPrepTM (60 w/V% iodixanol in
distilled water; Axis-Shield, Oslo, Norway) was diluted to 50,
30, and 10% in 0.25 M sucrose buffer (1 mM EDTA and 1mM
Tris-HCl, pH 7.4), and a discontinuous gradient was formed
by layering 1.33 or 2.66 mL of each solution in 5 mL (referred
to as small-scale DGUC) or 10 mL (referred to as large-scale
DGUC) polypropylene centrifugation tubes (Beckman Coulter,
Pasadena CA, United States). Rat cleared PFP was then layered
on to these gradients (0.5 mL on small-scale and 2 mL on
large-scale gradients). Afterward, samples were centrifuged in
SW55 Ti or Type 70.1 rotors for 24 h at 120,000 × g, 4◦C,
(Figure 1). Fractions of density gradient layers were collected
(F1–F10). From small-scale DGUC the volume of fractions was
500 µL in the case of both F1–F3 and F6–F9, and 330 µL for
F4, F5, and F10. From the large-scale DGUC, 1mL fractions were
collected uniformly. Samples were used within 24 h or stored at
−80◦C until use. The density of fractions was calculated based
on iodixanol concentration measured by spectrophotometry at
244 nm according to manufacturer’s instruction. Briefly, 10 µL
of iodixanol standards with concentrations between 1 and 40%
and DGUC fraction samples previously diluted 5,000-fold in
distilled water were pipetted into UV microplate wells (Thermo
Scientific, Waltham, MA, United States) in triplicates and read
by a spectrophotometer at 244 nm (Multiskan GO, Thermo
Scientific, Waltham, MA, United States). The density of samples
was calculated based on their iodixanol concentration.
Purification of EV-Rich Fractions by
Ultracentrifugation or Size-Exclusion
Chromatography
EV-rich fraction of small-scale DGUC, i.e., 300 µL of F6 fraction
with highest TSG101 signal was diluted to 5 mL with PBS, then
FIGURE 1 | Overview of sample preparation and EV-isolation by iodixanol
density gradient ultracentrifugation. Blood samples were centrifuged to
remove cells, large and medium-sized particles. The final supernatant platelet
free plasma was placed onto 10–30–50% iodixanol gradient layers, then
ultracentrifuged for 24 h. Ten fractions were collected from top to bottom and
characterized by electron microscopy, Western blot analysis and dynamic light
scattering. F, fraction; PFP, platelet-free plasma.
ultracentrifuged for 3 h at 100,000× g, 4◦C (SW55 rotor). Pellets
were resuspended in 200 µL PBS (Figure 2).
Bind-elute SEC was performed with modifications to what has
been previously described (Corso et al., 2017). EV-rich DGUC
fractions (1.5 mL from the pool of F6 + F7 + F8 in case of
large-scale DGUC) were loaded onto a HiScreen Capto Core
700 column (4.7 mL bed volume, GE Healthcare Life Sciences).
Flow rates and elute conditions were chosen according to the
manufacturer’s instructions. Content was eluted with 1× PBS
Frontiers in Physiology | www.frontiersin.org 3 October 2018 | Volume 9 | Article 1479
fphys-09-01479 October 19, 2018 Time: 18:23 # 4
Onódi et al. Extracellular Vesicle Isolation From Blood
FIGURE 2 | Schematic overview of EV purification methods from DGUC
fractions. EV-rich fractions with densities of 1.10–1.17 g/mL underwent
bind-elute chromatography by Capto Core 700 column, size exclusion
chromatography by Exo-Spin Midi column or classical 3 h pelleting by
ultracentrifugation (3 h UC). EV-rich isolates were characterized. EV,
extracellular vesicle; DGUC, density gradient ultracentrifugation; P6, pellet
from F6; EF, eluted fraction; ES, Exo-Spin fraction; DLS, dynamic light
scattering; EM, electron microscopy.
(12 × 500 µL, EF1–12), then the column was washed with 0.1M
NaOH in 30% 2-propanol, where CIPs were collected (CIP1-20,
20 × 500 µL; Figure 2). CIP1-20 fractions were immediately
pH-adjusted to 7.4 with 0.1M HCl solution in order to assess
the composition of bound proteins. Capto Core 700 column was
regenerated with 1M NaOH in 30% 2-propanol solution.
Exo-SpinTM gravity elution SEC was performed as previously
described (Welton et al., 2015). Pool of DGUC F5-7 (0.7 mL)
was loaded onto Exo-SpinTM Midi Columns with 10 mL bed
volume (Cell Guidance Systems; Cambridge, United Kingdom).
Conditions were chosen according to the manufacturer’s
instructions. Thirty EFs were collected (30 × 500 µL, ES1-30;
Figure 2).
Protein Concentration Measurement and
Western Blot Analysis
Of each fraction 100 µL sample was mixed with 11 µL of 10×
RIPA (Cell Signaling Technology, Danvers, MA, United States)
and incubated at 4◦C for 5 min. Protein concentration of
the samples was determined by bicinchoninic acid assay kit
(Thermo Scientific, Waltham, MA, United States). Western
blot was conducted as previously described in our laboratory
with minor modification (Baranyai et al., 2015). In brief, equal
volumes of samples or volumes containing equal amount of
protein from each sample were mixed with 1/5 volume of Lane
Marker (Thermo Scientific, Waltham, MA, United States) and
were loaded on 4–20% Tris-glycine sodium dodecyl sulfate-
polyacrylamide gels (Bio-Rad, Hercules, CA, United States), and
electrophoresed. Proteins were transferred onto polyvinylidene
difluoride membrane (Bio-Rad, Hercules, CA, United States)
at 350 mA for 2 h. Membranes were blocked in 5% non-fat
milk (Bio-Rad, Hercules, CA, United States) in Tris-buffered
saline containing 0.05% Tween-20 (0.05% TBS-T; Sigma, St.
Louis, MO, United States) for 2 h at room temperature, and
then were probed with primary antibodies overnight at 4◦C
(primary antibodies: anti-Alix [1:2,000; Cell Signaling, Danvers,
MA, United States; 2171S], anti-TSG101 [1:2,000; Abcam,
Cambridge, United Kingdom, ab83], anti-CD81 [1:2,000;
Santa Cruz Biotechnology, Dallas, TX, United States, sc-7637],
anti-Apolipoprotein A1 [1:2,000; Genetex, San-Antonio, TX,
United States; GTX112692-100], anti-Apolipoprotein B100/B48
[1:2,000; Merck, Darmstadt, Germany; MABS2046], anti-
fibrinogen chain beta (FGB) [1:10,000; Genetex, San-Antonio,
TX, United States; GTX54019-100] or anti-albumin [1:10,000;
Santa Cruz Biotechnology, Dallas, TX, United States, sc-
271605]). After 3 washes in TBS-T, membranes were incubated
with corresponding HRP-conjugated secondary antibodies (Cell
Signaling, Danvers, MA, United States) for 2 h and washed in
TBS-T. Signals were visualized after incubation with enhanced
chemiluminescence kit (Bio-Rad, Hercules, CA, United States)
by Chemidoc XRS+ (Bio-Rad, Hercules, CA, United States).
Image analysis was performed using Image LabTM software
(Bio-Rad, Hercules, CA, United States).
Dynamic Light Scattering
The size distribution of EVs was measured on a ZetasizerNano
(Malvern, United Kingdom) at 20◦C using an angle of 173
degrees and 633-nm laser (n = 3).
Transmission Electron Microscopy
Visualization of EVs was accomplished by resin-embedding or
the grid-adsorption method by transmission EM.
For resin-embedding EM, samples of interest underwent UC
(120,000 × g, 4◦C, 1 h) in 5 mL polypropylene centrifugation
tubes. The pellets were fixed with 4% paraformaldehyde,
postfixed in 1% osmium tetroxide (OsO4) for 20 min. After
rinsing with distilled water, they were dehydrated by ethanol
including block staining with 1% uranyl-acetate in 50% ethanol
for 30 min and embedded in Taab 812 (Taab). Ultrathin
sections were analyzed with a Hitachi 7100 (Hitachi Ltd, Japan)
electron microscope equipped by Veleta, a 4 megapixel side-
mounted transmission EM CCD camera (Olympus, Tokyo,
Japan). Contrast and brightness of electron micrographs were
edited by Adobe Photoshop CS3 (Adobe Incorporation).
For the grid-adsorption method, identical volumes of samples
and 1% OsO4 in water were mixed and placed onto Formvar
coated grids (Agar Scientific; Stansted Mountfitchet, United
Kingdom) for 15 min. Following three brief washes in distilled
water (3 × 1 min), the excess of the water was removed by
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FIGURE 3 | Analysis of protein composition of fractions collected from small-scale and large-scale DGUC. Protein concentration, representative Western blot images
and evaluation of each fraction from small-scale (A,B) and large-scale (C,D) density gradient ultracentrifugation (n = 3–6). Data are expressed as mean ± standard
error of mean. Relative band intensity was calculated by normalizing individual band intensity to the sum of corresponding total band intensity. F, fraction; FGB,
fibrinogen beta chain.
touching the edge of the grid to filter paper, and the grids were
air-dried and analyzed by transmission EM as described above.
RESULTS
Characterization of Fractions Separated
by Small-Scale or Large-Scale Density
Gradient Ultracentrifugation of Rat
Plasma
The first set of our experiments were aimed to test whether
large-scale or small-scale iodixanol DGUC were suitable for
separating EVs from soluble proteins and lipoproteins of the
blood plasma. Protein concentration (Figure 3A, line plot) of
collected fractions from small-scale DGUC showed a peak in F4
(10.56 ± 0.28 mg/mL; n = 3), while the total protein content
(Figure 3A, bars) was the highest in F3 (3.73 ± 0.31 mg/mL;
n = 3) and the lowest in high-density fractions (F8–10;
Figure 3A). Protein concentration and total protein content
showed different patterns due to the different volumes of the
fractions. Equal volumes of F1–10 were loaded for Western
blots to analyze the distribution of proteins of interest among
fractions from small-scale DGUC, which were then evaluated
by normalizing band intensities of each marker to the sum
of corresponding band intensities. EV-markers Alix, Tsg101
and CD81 were predominantly observed in F6, at a density
of 1.128 g/mL (61.5 ± 10.35%; 48.1 ± 5.8%; 41.9 ± 3.8%,
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respectively), while a smaller amount of markers was detected in
F5 (18.9 ± 4.1%; 31.3 ± 4.3%; 25.9 ± 2.9%) and F7 (5.8 ± 1.6%;
11.5 ± 2.2%; 15.4 ± 1.1%; Figures 3A,B). In addition, EV-
markers could be detected in F5 to F10 if samples with equal
amount of protein (10 µg) were loaded for Western blots,
indicating the presence of EV populations at higher densities
(1.174–1.287 g/mL; Supplementary Figure 1). After identifying
EV markers, we also tested markers for contaminants such
as lipoproteins and abundant plasma proteins. Chylomicron-
related Apo B48, LDL-related Apo B100 and HDL-related ApoA1
were mainly present in low-density fractions F1–4 (95.5 ± 3.5,
91.4 ± 2.8% and 83.8 ± 1.8%; n = 3), but a low proportion
of total Apo A1 was detected in EV-rich fractions as well (Apo
A1: 11.4 ± 1.2%; Apo B100: 1.35 ± 0.45; Apo B48: 0.63 ± 0.03;
in F6; Figures 3A,B). A moderate amount of albumin signal
was observed in F6 (9.91 ± 0.4%; n = 3), the majority of
albumin signals were detected in the lower density fractions F1–
5 (76.44 + 1.1% of total signal). Despite the efficient separation
of lipoprotein and albumin from EVs, fibrinogen (FGB) content
of F6 was significant (32.84 ± 1.53% of total signal; n = 3;
Figures 3A,B).
Samples from small-scale DGUC F6 and F7 were analyzed
using EM to visualize isolated EVs. To exclude the interference
of iodixanol with EM analysis, a control solution (20 w/V%
iodixanol in distilled water) was also examined (Supplementary
Figure 2A). Membrane-enclosed vesicles with a diameter of 48–
310 nm could be visualized with EM in F6 and F7 (n = 25;
Figure 4A). Selected fractions were examined by DLS to assess
the size distribution of vesicles, as well. DLS analysis of fractions
established that F6 contained mainly small-sized vesicles (mean
diameter: 38 ± 2 nm; n = 6), but a significant peak was also
observed at 4nm, likely due to the iodixanol content of the
samples (Figure 4C). Peaks with a diameter of 4 and 5,000 nm
corresponding to iodixanol were also present in DGUC fractions
(Figures 4C,D and Supplementary Figure 2).
DGUC was also tested at a larger scale to increase the loadable
sample volume and EV yield. 2 mL of plasma was layered onto
the top of total 8 mL of iodixanol gradient (Figure 1). Highest
protein content was observed in F6 and F7 in large-scale DGUC
(24.17 ± 0.99 mg, 30.67 ± 1.54 mg; n = 6; Figure 3C). EV-
markers Alix, Tsg101 and CD81 were detected in F7 at 1.146 g/mL
(38.2± 13.9%; 53.2± 0.6%; 62.8± 23.1%; n = 2–4), while a small
proportion of markers were observed in F6 and F8 (5.2 ± 1.4%,
3.6 ± 1.1% and 2.5 ± 0.6% in F6; 19.8 ± 7.7%; 36.2 ± 2.0%;
23.1 ± 5.9% in F8; n = 2–4). Still, a significant amount of
albumin was found in both F6 and F7 (55.2 ± 1.6%; n = 3).
Additionally, FGB was also present in F7–8 (65.5 ± 3.0%; n = 3).
The majority of Apo B48 and B100 were separated from EV-
rich F6–8 (3.3 ± 0.06% and 2.6 ± 0.1%; n = 3), but a small
proportion of ApoA1 was observed in fractions F6 (3.01± 1.29%;
n = 3; Figures 3C,D). Between DGUC fractions of fresh- or frozen
plasma there was no substantial difference in the distribution of
EV markers or contaminants (see Supplementary Figure 6). By
using EM and DLS analysis, the presence of vesicles in F7 was
confirmed; EVs in various size were identified by EM (Figure 4B),
while DLS evidenced the presence of smaller particles in F7 (mean
diameter: 18 ± 10 nm, n = 3). Peaks with a diameter of 4 and
5,000 nm corresponding to iodixanol were also present in F7 of
large-scale DGUC (Figure 4D).
Purification of EV-Rich Fractions of
Small-Scale DGUC by 3 h
Ultracentrifugation
The fraction F6 of the small-scale DGUC, which showed the
highest EV-content according to our Western blot analysis,
was diluted approximately 17-fold and centrifuged for 3 h at
100,000 × g, to reduce the remaining plasma contaminants and
iodixanol in the EV-rich fraction, then the pellet was analyzed
(Figure 2). UC for 3 h yielded notably less protein in pellets
(P6) compared to original DGUC fraction (109.4 ± 22.2 µg in
P6 vs. 3,475.9 ± 249.8 µg in loaded F6; n = 6; Supplementary
Figure 3A), while the iodixanol concentration was under
the detection limit in resuspended pellets as measured by
spectrometry at 244 nm. A high number of EVs was visualized in
P6 with EM (Supplementary Figure 3B), however, comparison
between F6 and P6 by Western blot showed that the band
intensity of EV markers was considerably lower after 3 h UC as
compared to that of corresponding F6 (Alix: 29.3± 0.2%; Tsg101:
24.4 ± 2.4%; CD81: 16.5 ± 1.2%; n = 3). In addition, signals
of albumin and lipoprotein markers were also reduced, but a
high amount of FGB was still present in the pellet as compared
to EVs or other contaminants (albumin: 10.1 ± 1.7%; ApoA1:
24.3 ± 5.9%; Apo B48: 24.4.0 ± 2.2%; Apo B100: 17.0 ± 3.8%;
FGB: 53.1 ± 2.1%; n = 3; Supplementary Figures 3C,D).
Furthermore, a significant amount of vesicles was also detectable
in the supernatant by Western blot obtained after 3h UC
evidencing the low efficiency of pelleting EVs by 3 h of UC
(Supplementary Figure 3E).
Purification of EV-Rich Fractions of
Large-Scale DGUC by HiScreen
CaptoCore700 Bind-Elute Size-Exclusion
Chromatography
The applicability of BEC using HiScreen Capto Core 700 columns
for further purification of EV-rich DGUC fractions was also
studied. Since the column has high binding capacity for proteins
(13 mg ovalbumin/mL of resin, Corso et al., 2017), and since
our preliminary experiments suggested a high loss of EVs if
samples with lower volume and protein concentration are applied
onto this column (data not shown), 1.5 mL pool of EV-rich
fractions F6, F7, and F8 of large-scale DGUC with total protein
contents of 28.36 ± 1.43 mg were loaded onto the column.
Then 12 eluted fractions (EF1-12) were analyzed. The total
protein amount in EF fractions was lower as compared to the
loaded large-scale DGUC fractions (295.3 ± 121.3 µg eluted
vs. 28.4 ± 1.4 mg input) (Figure 5A). The majority of signals
for Alix, Tsg101 and CD81 were found in EF6-9. Albumin and
Apo B100 were under detection limit in EF1–12, however, FGB
was detectable in EV-containing fractions EF2–EF6 (Figure 5B).
DLS analysis of fractions established that EF6 and EF7 contained
small-sized vesicles (mean diameter: 24.4 ± 5.1 nm, n = 3; and
24.4 ± 4.9 nm, n = 3), and the iodixanol-specific peaks (mean
diameter: 4 and 5,000 nm) were also present (Figure 5C and
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FIGURE 4 | Morphological analysis of extracellular vesicles isolated by small-scale or large-scale DGUC. Representative resin-embedding transmission electron
microscopy images on extracellular vesicles from small-scale DGUC F6 (A) and large-scale DGUC F7 (B). Dynamic light scattering measurement was performed
from the small-scale (C) and large-scale (D) EV-rich fractions in parallel with corresponding control iodixanol solution (n = 3–6) Data are expressed as
mean ± standard error of mean. DGUC, density gradient ultracentrifugation; F, fraction; EV, extracellular vesicle.
Supplementary Figure 2). In order to remove bound proteins,
the column was washed using 0.1M NaOH in 30% 2-propanol,
and CIP fractions were collected (CIP1-20). CIP5-15 contained
the highest protein concentrations, and therefore, were chosen
for Western blot to identify the composition of proteins bound
by the column. CIP fractions included high amounts of albumin
and FGB, but EV markers were also detectable, thus indicating
that the column retained significant amount of EVs as well
(Supplementary Figure 4).
Purification of EV-Rich Fractions by
Exo-SpinTM Size-Exclusion
Chromatography
Classical SEC by Exo-SpinTM was also evaluated for EV-isolation.
A pool of small-scale DGUC fractions F5–7 with the highest EV-
content (700 µL with 4.8± 0.3 mg total protein) was loaded onto
Exo-SpinTM columns with 10 mL bed volume. Then 30 fractions
of 500 µL were collected (ES1-30). Proteins were found in
fractions from ES10, while maximum protein concentration was
observed in ES18 (0.91 ± 0.02 mg/mL). In addition, significant
amount of iodixanol was only detected in ES17 (Supplementary
Figure 5A). According to Western blot analysis of ES8–18, EV-
markers were present in ES12–18 with significant amounts of
impurities (Supplementary Figure 5B).
DISCUSSION
Here we described an isolation method for EVs from fresh or
frozen blood plasma based on iodixanol DGUC followed by
BEC. The current method yields EVs in higher amounts than
previously described isolation techniques, such as UC and SEC,
without lipoprotein and albumin contamination. However, we
also report that fibrinogen may be a significant contaminant in
EV isolates from blood plasma. This is the first demonstration
that isolation of lipoprotein- and albumin-free EVs from blood
plasma can be achieved by DGUC followed by BEC. This comes
at the expense of reduced EV yield, however.
Since the efficiency of discontinuous iodixanol DGUC used
alone, or in combination with prior UC or filtration was low
or has not been determined (Kalra et al., 2013; Karimi et al.,
2018), here we optimized iodixanol DGUC by reducing the ratio
of gradient to sample volume and by increasing UC time. As a
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FIGURE 5 | - Analysis of Capto Core 700 elution fractions. Average of total protein content (A), protein and iodixanol concentration and representative Western blot
images (B) from EF2–12 with corresponding loaded DGUC fractions F6–8 (n = 3). Dynamic light scattering measurement (C) was performed from EF6–7 (n = 3).
Data are expressed as mean ± standard error of mean. DGUC, density gradient ultracentrifugation; EF, eluted fraction.
result, our small-scale DGUC protocol separated the majority of
EVs from the vast majority of lipoproteins with a high efficiency
(42–62% of EVs co-isolated with only 1–3% of lipoproteins in F6),
which would lead to a significant improvement in the reliability
of downstream analyses (Sluijter et al., 2018). We also report
that our DGUC approach reduced the amount of soluble protein
contaminants, i.e., albumin and fibrinogen, which have been
identified as some of the most abundant contaminants of EV
preparations (Baranyai et al., 2015; Foers et al., 2018; Karimi
et al., 2018). Nevertheless, we identified a small proportion of EVs
at higher densities, confirming previous findings (Bobrie et al.,
2012), suggesting that composition, hence function of a minority
of EVs in the blood plasma might be substantially different from
that of traditionally studied EV populations.
Additionally we investigated the effect of increased gradient to
sample ratio on separation efficiency. Large-scale DGUC showed
a separation pattern similar to our small-scale DGUC protocol.
However, the resolution was reduced as higher proportion of
albumin and HDL contamination was observed in the EV-
rich fractions, which is in contrast to findings of a previous
study (Karimi et al., 2018). This finding may result from
the different type of rotors in small- and large-scale DGUC
experiments. The difference in gradient formation between the
applied swing-out and fixed angle rotor may affect the migration,
distribution and composition of EV subpopulations in the
gradient. Also, the differences in separation pattern may arise
from the diluting effect of the increased volume of blood plasma
(density: 1.025 g/mL) on the high-density fractions which may
reduce separation efficiency and shift fractions (Steensgaard et al.,
1975). Thus we can conclude that DGUC is scalable only by
maintaining gradient to sample ratios of approximately 8:1.
Furthermore, our results also confirm that not only
lipoproteins, but aggregates of soluble plasma proteins may
appear at a wide range of buoyant densities, as shown before
(Aatonen et al., 2014). Our data suggests that separation methods
relying solely on differences in density may not be suitable for
EV isolation from blood and that additional purification steps
may be necessary since impurities with high binding capacities
for various biological substances and chemicals, such as albumin,
may significantly alter the results of functional- and in vivo
studies on EVs. We can thus see that the 24 h-long DGUC
is applicable as a first-step method for the isolation of EVs
from blood plasma to reduce lipoprotein- and proteinaceous
contaminations.
Three different methods were tested for second-step
purification of EV-rich fractions from DGUC in order to
increase the purity of our isolates. Firstly, classical purification
by pelleting UC for 3 h was performed on small-scale DGUC
fractions to avoid co-isolation with lipoproteins. Recovery of
EVs after 3 h UC was low, which is in accordance with our
previous observations (Baranyai et al., 2015) and reports by
others (Momen-Heravi et al., 2012; Vergauwen et al., 2017).
UC decreased the amount of albumin, however, the relative
fibrinogen content increased, suggesting that fibrinogen may
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tend to form high-density aggregates or fibrin fibers during the
isolation procedure which would further limit the applicability
of UC as a second-step purification method.
We also tested a commercially available SEC column for the
further purification of EV-rich DGUC fractions. We observed
that no further purification from lipoproteins or proteins was
achieved by this method, which is in accordance to previous
findings by our workgroup and others, showing that only a
minor fraction of EVs isolated from rat blood plasma could be
separated from albumin by SEC (Boing et al., 2014; Baranyai et al.,
2015; de Menezes-Neto et al., 2015). In addition, heterogeneity
of protein contaminants of EV isolates obtained from blood
by DGUC followed by SEC has been assessed inadvertently
by a proteomic analysis by Karimi et al. (2018) who detected
several hundred non-vesicular protein entities in their EV
preparations, the abundance of which in several cases even
exceeded that of the EV-associated proteins. These data suggest
that SEC products currently available may not be applicable
in workflows to increase purity of EV-rich fractions from
DGUC. However, since our results indicate that EVs from
rat plasma have a lower average diameter as compared to
human EVs (Baranyai et al., 2015), certain SEC matrices may
be useful for the isolation of EVs from the blood of different
species.
Bind-elute chromatography with Capto Core 700 columns was
applied to our study successfully for the first time in the literature
to further purify EV-rich DGUC fractions, confirming previous
results of Corso et al. (2017) on EVs isolated from cell culture
supernatant and displaying the feasibility of the use of BEC as a
second-step for EV purification from blood plasma. BEC yielded
approximately three-fold higher amount of proteins than 3 h UC
without significant dilution where contaminating albumin and
ApoA1 signals were under the detection limit, resulting in EVs
in sufficient amount for rodent in vivo experiments. However,
since input EV signals were significantly higher than that of
in the separated EV fractions, our findings suggest that Capto
Core 700 retained not only small molecules, but also a fraction
of EVs as well. This shows that the efficiency of this method
may require further refinement. Furthermore, the successful
separation of EVs from albumin and ApoA1 suggests that they
may not be integral parts of EV proteome, but contaminants
in EV preparations which are difficult to remove. In contrast,
and in accordance with previous findings with different isolation
methods (Aatonen et al., 2014; Roura et al., 2018), fibrinogen
was detected in early EV-rich fractions after purification on
Capto Core 700. This suggests that fibrinogen may have a strong
interaction with certain EV subpopulations, or it could also be
hypothesized that fibrinogen contamination is partially caused
by coagulation during isolation, since EVs and particles have
been shown to possess pro-coagulant properties (Siljander et al.,
1996). To lower or remove fibrinogen contamination, further
investigation is needed.
We found that in fractions of large- and small-scale DGUC
and BEC EV subpopulations with distinct marker patterns are
enriched. This phenomenon was described in other papers
previously. For example, in one of our earlier studies we
observed that a certain population of EVs that were positive
for TSG101 but not for CD63 eluted later than double positive
vesicles when separated by SEC on Sephacryl S400 from rat
blood plasma (Baranyai et al., 2015). Elsewhere, Western blot
analysis using several EV markers demonstrated the separation
of subpopulations of EVs from blood by iodixanol gradient UC
and SEC (Karimi et al., 2018). Similar results were obtained
by UC of cell supernatants (Jeppesen et al., 2014), suggesting
variable sedimentation characteristics and marker composition of
EV subpopulations.
Our current results indicate that while certain high-abundance
contaminants could be removed from EV isolates, some
components of the blood plasma cannot be separated from
EVs by currently available technologies with reasonable efforts.
Therefore, it is plausible that for different downstream analyses,
different EV isolation methods must be applied, since certain
studies may require higher purity EVs, but others may tolerate
the presence of certain contaminants. Nevertheless, despite the
remaining contaminants, e.g., fibrinogen, EV isolates obtained by
the current method have the potential applicability in vitro and
in vivo non-clinical studies with appropriate control groups to
distinguish the effects of EVs and contaminants. EVs isolated by
our method may advance studies on use of EVs in tumor therapy
(Rolfo et al., 2014; Lam et al., 2015) or tissue repair, e.g., after
cardiac ischemia/reperfusion injury (Giricz et al., 2014; Barile
et al., 2017; Sluijter et al., 2018).
This study faces certain limitations. We have not evaluated
the exact efficiency of EV isolation by Capto Core 700 due
to the high difference between loaded and yielded protein
content. Here we assessed only albumin and fibrinogen as protein
contaminants of EV isolates. Nevertheless, since a multitude
of other contaminants have been identified in EVs obtained
by multi-step methods (Karimi et al., 2018), determining the
presence or concentration of certain other contaminants may
also be necessary for specific downstream applications of the
EV isolates. Furthermore, investigation on functionality of EVs
obtained by the current method has not been performed.
CONCLUSION
In summary, we report an EV isolation method from blood
plasma based on iodixanol DGUC which is able to minimize
lipoprotein contamination while keeping high separation
efficiency. Although further purification of EV-rich DGUC
fractions by BEC to remove soluble blood components results
in EVs devoid of albumin and lipoproteins, but at the expense
of yield. Furthermore, certain blood plasma components still
remain in EV isolates obtained by DGUC and BEC. Therefore,
it is likely that for specific application of EV-rich fractions,
development of individual EV isolation methods should be
considered.
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